The stakes are considerable. Renal cell carcinoma accounted for roughly 440,000 new diagnoses and 180,000 deaths worldwide in 2022, and clear cell renal cell carcinoma, abbreviated ccRCC, makes up 70 to 80 percent of those cases. While targeted therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors have improved outcomes for many patients, sarcomatoid differentiation remains a grim turning point. It appears in about 4 to 5 percent of renal cancers, more frequently in the clear cell subtype than in papillary or chromophobe tumors, and is thought to represent a dramatic activation of epithelial-to-mesenchymal transition, the biological program by which epithelial cells abandon their tight connections and acquire the motile, spindle-shaped character of mesenchymal cells.

Under the microscope, this shift is unmistakable once seen: an abrupt transition from orderly epithelial architecture to pleomorphic spindle cells, with loss of the classical features that define ccRCC. Yet catching it early is notoriously difficult. Kidney tumors sit deep in the retroperitoneum, so up to a quarter of patients already have metastatic disease at diagnosis, and among those, roughly 20 percent harbor sarcomatoid features. Needle biopsies, the main alternative to surgery for patients too frail for nephrectomy, frequently miss sarcomatoid regions entirely because of sampling limitations. The Porto team, led by Fernanda Fernandes-Pontes and senior authors Vera Miranda-Gonçalves and Carmen Jerónimo, set out to find a molecular fingerprint that could reveal sarcomatoid change even when the biopsy shows only conventional tumor.

Their strategy began with publicly available data from The Cancer Genome Atlas, accessed through the cBioPortal for Cancer Genomics. From the Kidney Renal Clear Cell Carcinoma Firehose Legacy dataset, they filtered out cases lacking clear histological annotation, leaving 33 tumors with documented sarcomatoid features and 50 conventional ccRCC tumors. Using the Shiny Methylation Analysis Resource Tool, or SMART App, they extracted CpG sites, the cytosine-guanine dinucleotides where methyl groups attach to DNA, from promoter regions within 1,500 base pairs upstream of each gene’s transcription start site, restricting the analysis to CpGs located within CpG islands as annotated by the UCSC genome browser.

From an extensive literature review anchored on a molecular characterization of sarcomatoid renal cancer by Motzer and colleagues, the researchers compiled 76 candidate genes spanning angiogenesis, cell cycle regulation, signaling pathways, cellular differentiation, metabolism, epigenetic enzymes, and immune function. In the TCGA cohort, 64 of these genes were significantly downregulated in sarcomatoid tumors and 12 were upregulated. The team then applied a crucial filter: they searched for genes whose promoter methylation levels anti-correlated with their transcript levels, using Spearman’s correlation coefficient between methylation beta-values from the Illumina HumanMethylation450 array and log2-transformed TPM expression values from RNA sequencing. This inverse relationship is the statistical signature of a gene being silenced by its own promoter methylation.

Two genes emerged with striking clarity. CDHR5, a mucin-like cadherin family member involved in cell adhesion, showed three promoter CpGs with significant inverse correlations ranging from Rho of −0.34 to −0.41, and all three sites were significantly more methylated in sarcomatoid tumors. UPB1, an enzyme catalyzing the final step of pyrimidine degradation, displayed six inversely correlated CpGs with correlations from −0.11 to −0.75, two of which were significantly hypermethylated in the sarcomatoid group. Correspondingly, both genes showed significantly reduced transcript levels in sarcomatoid ccRCC. A third gene, TLCD1, which regulates the incorporation of long-chain polyunsaturated fatty acids into cell membranes and is tied to metabolic reprogramming, was upregulated in silico and included for validation, though its role would prove more complicated.

To confirm these computational findings in real tissue, the team assembled a cohort of 88 formalin-fixed, paraffin-embedded tumor samples from nephrectomies performed between 2001 and 2024 at their tertiary cancer center, including 34 tumors with sarcomatoid differentiation. A dedicated uropathologist annotated both the truly sarcomatoid regions and conventional ccRCC areas on stained slides for precise macrodissection. RNA was extracted and reverse-transcribed for quantitative PCR analysis of transcript levels, while DNA was bisulfite-converted, a chemical treatment that converts unmethylated cytosines to uracil while leaving methylated cytosines intact, allowing methylation to be quantified by multiplex quantitative methylation-specific PCR with primers and TaqMan probes designed to cover the exact CpGs identified in the TCGA analysis.

The validation was unambiguous. Sarcomatoid tumors showed significantly higher promoter methylation of both CDHR5 and UPB1, along with significantly lower transcript levels of both genes, mirroring the TCGA data. Immunohistochemistry on 64 cases, 32 of each type, revealed that UPB1 protein, which localizes to the cytoplasm, was significantly reduced in sarcomatoid tumors with a p-value of 0.0022, while CDHR5 membrane staining showed the same downward trend without reaching statistical significance. Notably, UPB1 immunostaining scores anti-correlated with the proliferative index measured by Ki67, and UPB1 protein was significantly lower in stage T2 through T4 sarcomatoid tumors compared to stage T1, suggesting a putative tumor-suppressor role. TLCD1, by contrast, failed to show significant expression differences in the tissue cohort, prompting the authors to hypothesize that other epithelial-to-mesenchymal transition pathways drive sarcomatoid change in ccRCC.

The clinical implications sharpened when the team examined biomarker performance. Individually, CDHR5 methylation discriminated sarcomatoid from conventional tumors with 70.4 percent sensitivity, while UPB1 methylation achieved 74.1 percent sensitivity with similar specificity. Combined into a two-gene panel, the markers reached 78.7 percent specificity and 63.0 percent sensitivity, with positive and negative predictive values in the same range. More strikingly, elevated CDHR5 methylation was significantly associated with metastatic disease at diagnosis, with a p-value of 0.0159, and with advanced stage III/IV disease at p equal to 0.0488. The authors propose a plausible mechanism: as a mucin-like adhesion protein, reduced CDHR5 expression, driven by promoter hypermethylation, may loosen tumor cell cohesion, enhance invasion and migration, and facilitate access to blood vessels, thereby promoting metastatic dissemination.

The researchers caution that this is a retrospective and exploratory study, and that functional validation of the genes’ roles and regulatory mechanisms remains an important next step. Yet the translational potential is clear. Because aberrant DNA methylation occurs early in tumorigenesis and can be detected in cell-free DNA circulating in blood, the CDHR5 and UPB1 methylation signature could, if validated in larger studies and liquid biopsies, provide a non-invasive molecular fingerprint of sarcomatoid differentiation. Such a test would complement histopathological work-up of core biopsies, flag patients whose conventional-appearing tumors harbor hidden aggressive biology, and inform therapeutic decisions, since sarcomatoid tumors are generally more resistant to tyrosine kinase inhibitors but may respond better to anti-PD-L1 immunotherapy. For a cancer that often hides its worst features until it is too late, a pair of silenced genes may prove to be the warning sign clinicians have been waiting for.

Subject of Research: Epigenetic regulation of CDHR5 and UPB1 promoter methylation in sarcomatoid clear cell renal cell carcinoma

Article Title: CDHR5 and UPB1 expression associated with promoter methylation in sarcomatoid differentiated clear cell renal cell carcinoma

Article References: CDHR5 and UPB1 expression associated with promoter methylation in sarcomatoid differentiated clear cell renal cell carcinoma. (n.d.). https://doi.org/10.1186/s43682-026-00053-7

Image Credits: AI Generated

DOI: 10.1186/s43682-026-00053-7

Keywords: clear cell renal cell carcinoma, sarcomatoid differentiation, DNA methylation, CDHR5, UPB1, epigenetics, biomarkers, liquid biopsy, The Cancer Genome Atlas, kidney cancer, epithelial-to-mesenchymal transition, quantitative methylation-specific PCR

The premise behind the work rests on a growing body of evidence that depression is not purely a disorder of neurotransmitters. Brain imaging studies have repeatedly shown altered energy metabolism in depressed patients, and post-mortem tissue analyses have hinted at mitochondrial dysfunction in neural circuits that govern mood. Mitochondria do far more than generate ATP; they regulate calcium signaling, produce reactive oxygen species, and even help decide when a cell should die. When these processes falter, neurons may become less resilient to stress, and inflammatory signaling can spiral. What has been missing is a precise, reproducible set of genes that ties mitochondrial metabolism to the clinical reality of major depressive disorder, and that is precisely the gap the new study set out to fill.

The team, led by Lianyong Zou and corresponding author Jie Li of Tianjin Anding Hospital and the Shandong Mental Health Center, began with a classic bioinformatics strategy. They scoured the Gene Expression Omnibus, a public repository maintained by the National Center for Biotechnology Information, for datasets comparing gene expression in blood or brain samples from people with major depressive disorder against healthy controls. From these datasets they extracted differentially expressed genes, the molecular transcripts that rise or fall significantly in depression. In parallel, they compiled a reference list of 1,234 genes known to participate in mitochondrial metabolism, drawn from public pathway databases. The intersection of these two lists, genes that are both dysregulated in depression and directly involved in mitochondrial metabolism, formed the starting pool of candidates.

That intersection alone would have produced a long list, so the researchers turned to machine learning to whittle it down. Using expression-screening algorithms trained on the depression datasets, they iteratively ranked and filtered the candidate genes, searching for those whose expression patterns best discriminated depressed patients from controls. The process converged on three genes: ALDH3B1, ALOX15B, and UPB1. Each has a distinct biochemical role. ALDH3B1 encodes an aldehyde dehydrogenase involved in detoxifying reactive aldehydes, byproducts of lipid peroxidation that can damage proteins and DNA. ALOX15B encodes a lipoxygenase enzyme that oxidizes polyunsaturated fatty acids into signaling lipids, many of which are potent mediators of inflammation. UPB1, or beta-ureidopropionase, participates in the breakdown of pyrimidine bases, connecting the gene to nucleotide metabolism and, indirectly, to cellular energy economics.

To test whether these three genes could serve as a practical diagnostic signature, the team built a nomogram, a statistical tool that combines the expression values of multiple genes into a single risk score. In the training dataset, the three-gene nomogram showed moderate discriminatory performance, meaning it could separate depression cases from controls better than chance, though not with the precision required of a standalone clinical test. The authors are careful on this point: the nomogram is a proof of concept, a demonstration that a compact mitochondrial gene panel carries real signal, rather than a finished diagnostic instrument. Still, in a field where biomarkers for depression have been notoriously hard to pin down, even moderate performance from a three-gene panel is noteworthy.

The researchers then asked what biological programs these genes travel with. Using gene set enrichment analysis, a technique that examines whether entire pathways shift in concert with a gene of interest, they found that ALDH3B1, ALOX15B, and UPB1 correlated with transcriptional programs involving lysosomal function, protein turnover, ribosomal processes, cellular signaling, and energy metabolism. This is a coherent picture: lysosomes are the cell’s recycling centers, ribosomes its protein factories, and mitochondria its power grid, and all three must be coordinated for a cell to stay healthy. A simultaneous perturbation across these systems is consistent with the idea that depression involves a broad breakdown in cellular housekeeping, not a single faulty switch.

One of the more striking findings came from immune infiltration analysis. By estimating the relative abundance of different immune cell types from gene expression data, the team detected significant differences in six immune-cell signatures between depressed patients and controls. Several myeloid-cell signatures, which encompass monocytes, macrophages, and related innate immune cells, correlated with the expression of the candidate genes. This dovetails with a decade of research linking depression to low-grade systemic inflammation, and it suggests that the mitochondrial genes identified here may sit at the junction between metabolic dysfunction and immune activation. If lipid-peroxidation enzymes like ALOX15B are upregulated in depression, they could generate oxylipin signaling molecules that both recruit myeloid cells and alter neuronal function, offering a mechanistic bridge between the two processes.

The study also ventured into therapeutics. An exploratory drug-gene interaction analysis identified approved medications predicted to interact with each candidate gene: four drugs for ALDH3B1, eighteen for ALOX15B, and two for UPB1. The authors frame this as hypothesis generation rather than treatment guidance, and appropriately so. Drug-gene interaction databases catalog known pharmacological targets, but whether any of these compounds could meaningfully modulate the course of depression through these genes remains entirely untested. Still, the exercise illustrates a modern trend in psychiatry research: using computational pipelines to surface repurposing candidates that can then be prioritized for laboratory and, eventually, clinical scrutiny.

The critical step was experimental validation. The team performed reverse transcription quantitative PCR, a sensitive technique for measuring gene expression, on samples from depressed patients and healthy controls, with ethical approval from the Shandong Mental Health Center and written informed consent from all participants. The results were encouraging but nuanced. ALDH3B1 was significantly elevated in depression, with a p-value of 0.0138. ALOX15B showed an even stronger signal, with a p-value below 0.0001, making it the standout candidate of the study. UPB1 trended upward with a fold change of 1.3245 but did not reach statistical significance, with a p-value of 0.4842. In their conclusions, the authors classify ALDH3B1 and ALOX15B as preliminary candidate genes supported by both bioinformatics and experimental observation, while UPB1 remains a bioinformatics-derived candidate awaiting independent validation.

The researchers are candid about the limitations. The RT-qPCR cohort was small, and the authors explicitly state that the candidates require further investigation in larger independent cohorts. Blood-based gene expression, the most accessible sample type for psychiatric studies, may not perfectly mirror what happens in the brain, and depression is clinically heterogeneous, encompassing patients whose biology may differ substantially. Yet the study’s architecture, from public data mining through machine learning to molecular validation, offers a template for how psychiatric biomarker research can proceed in the era of big data. If larger studies confirm that ALOX15B and ALDH3B1 are reliably dysregulated in depression, they could become part of a much-needed molecular toolkit: objective measures to complement subjective diagnostic interviews, and potential targets for therapies aimed at the metabolic and inflammatory undercurrents of the illness. For now, the message is one of cautious excitement. The mitochondria, long dismissed as mere cellular plumbing, are increasingly looking like central characters in the biology of mood, and three genes may be the first reliable thread in a story that is only beginning to unravel.

Subject of Research: Mitochondrial metabolism-related candidate genes associated with major depressive disorder identified through bioinformatics and RT-qPCR validation

Article Title: Mitochondrial metabolism-related candidate genes in major depressive disorder: integrative bioinformatics analysis and RT-qPCR assessment

Article References: Zou, L., Zhao, Y., Han, C., Liu, J., Liu, H., Chen, Z., Li, Q., & Li, J. (2026). Mitochondrial metabolism-related candidate genes in major depressive disorder: integrative bioinformatics analysis and RT-qPCR assessment. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08636-3

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08636-3

Keywords: major depressive disorder, mitochondrial metabolism, ALDH3B1, ALOX15B, UPB1, bioinformatics, machine learning, RT-qPCR, gene expression, immune infiltration, biomarkers, BMC Psychiatry